Information Provided By: 
Fly News Breaks for June 14, 2017
STML
Jun 14, 2017 | 07:40 EDT
Cowen analyst Boris Peaker said he sees significant upside for Stemline shares from current levels as he believes the company has a real drug for a highly unmet medical need in an orphan oncology indication, namely blastic plasmacytoid dendritic cell neoplasm. Although there are safety concerns, he believes there is a high chance of FDA approval and commercial uptake. Peaker called Stemline a best small/mid-cap idea and reiterated his Outperform rating on the shares.
News For STML From the Last 2 Days
There are no results for your query STML
